Patents by Inventor Ian G. Charles

Ian G. Charles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040006434
    Abstract: A method for identifying an essential gene of an organism, which method comprises: (i) providing a library of transposon insertion mutants of the said organism, wherein the transposon comprises an RNA polymerase recognition sequence; (ii) isolating chromosomal DNA from the library of (i), (iii) digesting the chromosomal DNA with a restriction endonuclease that is capable of cutting 5′ of the RNA polymerase recognition site in the transposon and 3′ of the RNA polymerase recognition site in the chromosomal DNA flanking the transposon; (iv) self-ligating the digested DNA, (v) amplifying the self-ligated DNA by inverse PCR (iPCR), (vi) transcribing RNA from the amplified DNA, (vii) hybridising the transcribed RNA with an oligonucleotide array; and (viii) identifying a probe on the oligonucleotide array which corresponds to an essential gene of the organism.
    Type: Application
    Filed: February 3, 2003
    Publication date: January 8, 2004
    Applicant: ARROW THERAPEUTICS LIMITED
    Inventors: Ian G. Charles, Andrew Allen, Duncan J. Maskell
  • Patent number: 5589384
    Abstract: A fusion protein suitable for use as a vaccine comprises an amino acid sequence having biological activity which is fused via an intervening hinge comprising from two to eight glycine-proline repeats to the C-terminus of sufficient of the amino acid sequence of a B subunit of an enterotoxin which is capable of ADP-ribosylation of a GTPase.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: December 31, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Martin J. Lipscombe, Ian G. Charles, Neil F. Fairweather
  • Patent number: 5547664
    Abstract: The invention concerns a vaccine comprising an attenuated Salmonella bacterium which contains a nirB promoter operably linked to a DNA sequence encoding a heterologous protein. The nirB promoter directs expression of the heterologous protein in a host it is wished to vaccinate.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: August 20, 1996
    Assignee: Burroughs Wellcome Co.
    Inventors: Ian G. Charles, Steven N. Chatfield, Neil F. Fairweather
  • Patent number: 5322774
    Abstract: A process for the preparation of a protein, which process comprises culturing under such conditions that the protein is obtained cells infected with a recombinant baculovirus having a promoter, capable of directing the expression of a gene in the cells, operably linked to a heterologous gene which encodes the protein and which is preceded by a leader sequence comprising: T A A T C A T C C A C A G G A G A C T T T C T G [SEQ. ID NO: 1].
    Type: Grant
    Filed: October 23, 1991
    Date of Patent: June 21, 1994
    Assignee: Burroughs Wellcome Co.
    Inventors: Timothy C. Peakman, Martin J. Page, Ian G. Charles